Inventor · disambiguated record
Dhanapalan Nagarathnam
Also filed as: NAGARATHNAM DHANAPALAN
62 granted patents·24 pending applications·1,747 citations·filing 1994–2024
99Inventor score
Files withSYNAPTIC PHARMA CORP22RHIZEN PHARMACEUTICALS SA16BAYER PHARMACEUTICALS CORP10NAGARATHNAM DHANAPALAN7GILEAD PHARMASSET LLC6
Top patents by PatentIndex Score
86 records- 0199US8906880B2Nucleoside phosphoramidate prodrugsGILEAD PHARMASSET LLC·Filed 2014·Granted Dec 9, 2014·65 cites·11 claims
- 0298US11642361B2Nucleoside phosphoramidate prodrugsGILEAD SCIENCES INC·Filed 2020·Granted May 9, 2023·4 cites·3 claims
- 0398US9085573B2Nucleoside phosphoramidate prodrugsGILEAD PHARMASSET LLC·Filed 2013·Granted Jul 21, 2015·54 cites·28 claims
- 0498US8957046B2Nucleoside phosphoramidate prodrugsGILEAD PHARMASSET LLC·Filed 2014·Granted Feb 17, 2015·51 cites·2 claims
- 0598US8580765B2Nucleoside phosphoramidate prodrugsSOFIA MICHAEL JOSEPH·Filed 2012·Granted Nov 12, 2013·96 cites·14 claims
- 0698US8334270B2Nucleoside phosphoramidate prodrugsSOFIA MICHAEL JOSEPH·Filed 2011·Granted Dec 18, 2012·128 cites·25 claims
- 0798US8173621B2Nucleoside cyclicphosphatesDU JINFA·Filed 2009·Granted May 8, 2012·128 cites·46 claims
- 0897US9150579B2Selective PI3K delta inhibitorsRHIZEN PHARMACEUTICALS SA·Filed 2013·Granted Oct 6, 2015·34 cites·14 claims
- 0997US8759510B2Nucleoside cyclicphosphatesDU JINFA·Filed 2012·Granted Jun 24, 2014·76 cites·12 claims
- 1097US8735372B2Nucleoside phosphoramidate prodrugsGILEAD PHARMASSETT LLC·Filed 2013·Granted May 27, 2014·88 cites·2 claims
- 1196US9475818B2Selective PI3K delta inhibitorsRHIZEN PHARMACEUTICALS SA·Filed 2015·Granted Oct 25, 2016·17 cites·20 claims
- 1296US8957045B2Nucleoside phosphoramidatesGILEAD PHARMASSET LLC·Filed 2013·Granted Feb 17, 2015·39 cites·20 claims
- 1396US8716262B2Nucleoside phosphoramidatesSOFIA MICHAEL JOSEPH·Filed 2009·Granted May 6, 2014·66 cites·36 claims
- 1496US8716263B2Synthesis of purine nucleosidesCHUN BYOUNG-KWON·Filed 2009·Granted May 6, 2014·73 cites·24 claims
- 1596US8101773B2Hydroxy methyl phenyl pyrazolyl urea compounds useful in the treatment of cancerSMITH ROGER·Filed 2007·Granted Jan 24, 2012·58 cites·16 claims
- 1695US9585906B2Nucleoside phosphoramidate prodrugsGILEAD PHARMASSET LLC·Filed 2015·Granted Mar 7, 2017·11 cites·10 claims
- 1795US8563530B2Purine nucleoside phosphoramidateCHANG WONSUK·Filed 2011·Granted Oct 22, 2013·94 cites·28 claims
- 1895US6620815B1Oxazolidinones and uses thereofSYNAPTIC PHARMA CORP·Filed 2000·Granted Sep 16, 2003·50 cites·40 claims
- 1994US10072013B2Selective PI3K delta inhibitorsRHIZEN PHARMACEUTICALS SA·Filed 2017·Granted Sep 11, 2018·9 cites·20 claims
- 2094US9669033B2Selective PI3K delta inhibitorsRHIZEN PHARMACEUTICALS SA·Filed 2016·Granted Jun 6, 2017·10 cites·15 claims
- 2194US6720324B2Selective melanin concentrating hormone-1 (MCH1) receptor antagonists and uses thereofSYNAPTIC PHARMA CORP·Filed 2001·Granted Apr 13, 2004·51 cites·18 claims
- 2293US6787651B2Substituted indoles, pharmaceutical compounds containing such indoles and their use as PPAR-γ binding agentsSMITHKLINE BEECHAM CORP·Filed 2001·Granted Sep 7, 2004·72 cites·14 claims
- 2392US12121529B2Nucleoside phosphoramidate prodrugsGILEAD SCIENCES INC·Filed 2023·Granted Oct 22, 2024·0 cites·29 claims
- 2492US8551973B2Nucleoside analogsBAO DONGHUI·Filed 2009·Granted Oct 8, 2013·86 cites·10 claims
- 2589US7648986B2Substituted thieno[3,2-D]pyrimidines as Rho kinase inhibitorsBAYER HEALTHCARE LLC·Filed 2007·Granted Jan 19, 2010·16 cites·8 claims
- 2687US5767131ADihydropyridines and new uses thereofSYNAPTIC PHARMA CORP·Filed 1994·Granted Jun 16, 1998·38 cites·18 claims
- 2786US6943172B2Rho-kinase inhibitorsBAYER PHARMACEUTICALS CORP·Filed 2003·Granted Sep 13, 2005·20 cites·5 claims
- 2886US6903101B1Substituted pyridazines and fused pyridazines with angiogenesis inhibiting activityBAYER PHARMACEUTICALS CORP·Filed 2000·Granted Jun 7, 2005·21 cites·22 claims
- 2986US6689883B1Substituted pyridines and pyridazines with angiogenesis inhibiting activityBAYER PHARMACEUTICALS CORP·Filed 2000·Granted Feb 10, 2004·20 cites·6 claims
- 3086US6245773B15-(heterocyclic alkyl)-6-aryl-dihydropyrimidinesSYNAPTIC PHARMA CORP·Filed 1997·Granted Jun 12, 2001·34 cites·19 claims
- 3185US10981919B2Selective PI3K delta inhibitorsRHIZEN PHARMACEUTICALS SA·Filed 2020·Granted Apr 20, 2021·1 cites·13 claims
- 3285US10570142B2Selective PI3K delta inhibitorsRHIZEN PHARMACEUTICALS SA·Filed 2018·Granted Feb 25, 2020·2 cites·29 claims
- 3385US7678804B2Pyrimidine derivatives for treatment of hyperproliferative disordersBAYER HEALTHCARE LLC·Filed 2005·Granted Mar 16, 2010·4 cites·11 claims
- 3485US6159990AOxazolidinones as α1A receptor antagonistsSYNAPTIC PHARMA CORP·Filed 1998·Granted Dec 12, 2000·66 cites·38 claims
- 3584US10183037B2Nucleoside phosphoramidate prodrugsGILEAD PHARMASSET LLC·Filed 2017·Granted Jan 22, 2019·2 cites·19 claims
- 3683US9815831B23,5-disubstituted-3H-imidazo[4,5-B]pyridine and 3,5-disubstituted-3H-[1,2,3]triazolo[4,5-B] pyridine compounds as modulators of c-Met protein kinasesRHIZEN PHARMACEUTICALS SA·Filed 2013·Granted Nov 14, 2017·5 cites·32 claims
- 3781US10220035B2Compounds as modulators of protein kinasesRHIZEN PHARMACEUTICALS SA·Filed 2015·Granted Mar 5, 2019·2 cites·12 claims
- 3880US6924290B2Rho-kinase inhibitorsBAYER PHARMACEUTICALS CORP·Filed 2003·Granted Aug 2, 2005·14 cites·17 claims
- 3976US2021403475A1Novel selective pi3k delta inhibitorsRHIZEN PHARMACEUTICALS SA·Filed 2021·Application pending·0 cites
- 4075US9775841B2Compounds as modulators of protein kinasesNAGARATHNAM DHANAPALAN·Filed 2012·Granted Oct 3, 2017·2 cites·6 claims
- 4174US6727257B15-(heterocyclic alkyl)-6-aryl-dihydropyrimidinesSYNAPTIC PHARMA CORP·Filed 2000·Granted Apr 27, 2004·7 cites·42 claims
- 4274US2021401840A1Novel compounds as modulators of protein kinasesRHIZEN PHARMACEUTICALS SA·Filed 2021·Application pending·0 cites
- 4372US5942517A5-(heterocyclic alkyl)-6-aryl-dihydropyrimidinesSYNAPTIC PHARMA CORP·Filed 1997·Granted Aug 24, 1999·28 cites·29 claims
- 4471US12258350B1Crystalline forms of 4-ethoxy-n-(2-methoxyethyl)-n-methyl-3-(5-methyl-4-oxo-7-propyl-3,4-dihydroimidazo[5, 1-f][1,2,4]triazin-2-yl)benzenesulfonamideRETENSION PHARMACEUTICALS INC·Filed 2024·Granted Mar 25, 2025·0 cites·15 claims
- 4571US9777018B2Compounds as modulators of GPR-119RHIZEN PHARMACEUTICALS SA·Filed 2015·Granted Oct 3, 2017·1 cites·36 claims
- 4670US11020399B2Intermediates useful in the synthesis of compounds as modulators of protein kinasesRHIZEN PHARMACEUTICALS SA·Filed 2019·Granted Jun 1, 2021·0 cites·2 claims
- 4770US7582645B2Pyrimidine derivatives for treatment of hyperproliferative disordersBAYER PHARMACEUTICALS CORP·Filed 2004·Granted Sep 1, 2009·4 cites·10 claims
- 4870US6268369B15-(heterocyclic alkyl)-6-aryl-dihydropyrimidinesSYNAPTIC PHARMA CORP·Filed 1995·Granted Jul 31, 2001·28 cites·21 claims
- 4970US6211198B1Dihydropyridines and new uses thereofSYNAPTIC PHARMA CORP·Filed 1998·Granted Apr 3, 2001·12 cites·16 claims
- 5070US6172066B1Dihydropyrimidines and uses thereofSYNAPTIC PHARMA CORP·Filed 1997·Granted Jan 9, 2001·15 cites·19 claims
Showing the top 50 of 86 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when Dhanapalan Nagarathnam files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →